<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248348</url>
  </required_header>
  <id_info>
    <org_study_id>2394-05/02/2019</org_study_id>
    <nct_id>NCT04248348</nct_id>
  </id_info>
  <brief_title>Metaxa Hospital THromboprophylaxis Program in Oncological &amp; Surgical Patients</brief_title>
  <acronym>MeTHOS</acronym>
  <official_title>Metaxa's Thromboprophylaxis Program in Oncological &amp; Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metaxa Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metaxa Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During MeTHOS study will be collected Real World Data the clinical practice regarding
      Thromboprophylaxis in high thrombotic risk solid tumors patients undergoing surgical and /or
      chemotherapeutical treatment, for one year following the protocol initiation date.

      Specifically focus will be on the following:

        -  Number of thrombotic events

        -  Anti-thrombotic management dosage &amp; duration

        -  Any bleedings related to anticoagulation

        -  Patients' adherence and compliance
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of thrombotic events</measure>
    <time_frame>Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)</time_frame>
    <description>Measure the number of thrombotic events in the population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of bleedings related to anticoagulation</measure>
    <time_frame>Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)</time_frame>
    <description>Measure the number of observed bleeding events caused by the anticoagulation treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation drug dosage</measure>
    <time_frame>Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)</time_frame>
    <description>Record the antithrombotic drug dosage (IU/day), aiming to investigate the role of dosage for thrombotic events and bleedings (primary outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation drug duration</measure>
    <time_frame>Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)</time_frame>
    <description>Record the antithrombotic drug duration (in days). The aim is to investigate the role of antithrombotic duration for thrombotic events and bleedings (primary outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' compliance to anticoagulation treatment</measure>
    <time_frame>Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)</time_frame>
    <description>Record the compliance of patients' in antithrombotic treatment. A patient is considered to be compliant if the anticoagulation treatment was administered as prescribed (usually every day), otherwise it is non-compliant. The aim is to investigate the role of patient compliance for thrombotic events and bleedings (primary outcomes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation drug agent</measure>
    <time_frame>Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)</time_frame>
    <description>Record the anticoagulation drug agent. The aim is to investigate the role of different agents for thrombotic events and bleedings (primary outcomes)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Thrombosis</condition>
  <condition>Solid Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Molecular Weight Heparin</intervention_name>
    <description>Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Solid cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who were diagnosed with histological confirmed high thrombotic risk cancers
             (GI, thoracic, gynecologic and genitourinary) undergoing surgery

          2. Age â‰¥ 18 years

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          4. Life expectancy &gt;6 months

          5. Signed informed consent

        Exclusion Criteria

          1. Patients who were not diagnosed with histological confirmed high thrombotic risk
             cancers (GI, thoracic, gynecologic and genitourinary) undergoing surgery

          2. Age &lt; 18 years

          3. ECOG performance status &gt;2

          4. Life expectancy &lt;6 months

          5. Not signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikos Ziras, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Metaxa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Spyridon Xynogalos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metaxa Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikos Ziras, MD</last_name>
    <phone>+306932748495</phone>
    <email>zirasngr@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Spyridon Xynogalos, MD</last_name>
    <phone>+306932056426</phone>
    <email>sxyn@otenet.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Metaxa Hopital</name>
      <address>
        <city>Piraeus</city>
        <state>Attica</state>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Ziras, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Spyridon Xynogalos, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Metaxa Hospital</investigator_affiliation>
    <investigator_full_name>Nikolaos Ziras</investigator_full_name>
    <investigator_title>Head of Oncology Clinic</investigator_title>
  </responsible_party>
  <keyword>Thrombosis</keyword>
  <keyword>Cancer</keyword>
  <keyword>Heparin, Low Molecular Weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data may be provided upon a reasonable request.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04248348/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

